3-(piperidin-4-yl)-1H-indole hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(piperidin-4-yl)-1H-indole hydrochloride
• 英文别名: 3-(4'-Piperidyl)-indol-Hydrochlorid；4-(1H-indol-3-yl)piperidinium chloride；3-(4'-piperidyl)-indole hydrochloride；3-piperidin-4-yl-1H-indole;hydrochloride
• 化学式: C₁₃H₁₆N₂*ClH
• 分子量: 236.744
• InChiKey: LBGZMMNZWGMAGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.06
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  27.8
• 氢给体数：
  3
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(piperidin-4-yl)-1H-indole hydrochloride 在 盐酸 、 sodium periodate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 51.0h， 生成 5-[1-[2-[4-(trifluoromethyl)phenyl]acetyl]-4-piperidinyl]-1,3-dihydro-1,4-benzodiazepine-2-one
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME

  摘要：

  由式XI表示的杂环化合物，其药用盐、溶剂合物，或其药用盐的溶剂合物，以及其用途和含有该化合物的组合物。该化合物在结构上是新颖的，并具有良好的STAT5抑制活性。

  公开号：

  EP3960736A1
• 作为产物：
  描述：

  5-氯吲哚 在 palladium 10% on activated carbon 盐酸 、 甲酸铵 、 potassium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 46.0h， 生成 3-(piperidin-4-yl)-1H-indole hydrochloride
  参考文献：
  名称：

  [EN] INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
  [FR] DÉRIVÉS D'INDOLAMIDE ET COMPOSÉS ASSOCIÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DES MALADIES NEURODÉGÉNÉRATIVES

  摘要：

  本发明提供了新型化合物，以及这些新型化合物作为药物的使用，特别是用于预防或治疗神经退行性疾病，更具体地是一些神经系统疾病，例如统称为tauopathies的疾病，以及以细胞毒性α-突触核蛋白淀粉样蛋白生成为特征的疾病。本发明还涉及将所述新型化合物用于制造用于治疗此类神经退行性疾病的药物。本发明还涉及包括所述新型化合物的药物组合物，以及制备所述新型化合物的方法。

  公开号：

  WO2010142801A1

文献信息

• Phenoxyalkylamine derivatives useful as opioid receptor agonists
  申请人：——

  公开号：US20030171370A1

  公开（公告）日：2003-09-11

  A medicament useful for preventive and/or therapeutic treatment of nerve system diseases which comprises, as an active ingredient, a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof: 1 wherein, X represents a group represented by the following general formula (II), (III), (IV), (V), or (VI), 2 “A” represents a saturated or unsaturated 3- to 6-membered carbocyclic group and the like, “B” represents CH 2 and the like, “n” represents 0 to 2, R 1 represents a hydrogen atom, a halogen atom and the like, R 2 , R 3 , and R 7 to R 14 represent a hydrogen atom, a lower alkyl group which may be substituted and the like, R 4 represents a hydrogen atom, a lower alkyl group which may be substituted and the like, R 5 represents a hydrogen atom, a halogen atom and the like, R 6 represents a saturated or unsaturated monocyclic or bicyclic carbocyclic group and the like, and R 5 and R 6 , R 7 and R 8 , R 9 and R 10 , or R 11 and R 12 may bind to each other to form a cyclic structure.

  一种用于预防和/或治疗神经系统疾病的药物，其活性成分为以下通用式（I）或其药理学可接受的盐所代表的化合物： 其中，X代表以下通用式（II）、（III）、（IV）、（V）或（VI）所代表的基团，“A”代表饱和或不饱和的3-至6-成员碳环基团等，“B”代表CH2等，“n”代表0至2，R1代表氢原子、卤素原子等，R2、R3和R7至R14代表氢原子、可能被取代的较低烷基基团等，R4代表氢原子、可能被取代的较低烷基基团等，R5代表氢原子、卤素原子等，R6代表饱和或不饱和的单环或双环碳环基团等，且R5和R6、R7和R8、R9和R10，或R11和R12可以结合在一起形成环状结构。
• Cinnamide compound
  申请人：Kimura Teiji

  公开号：US20060004013A1

  公开（公告）日：2006-01-05

  The present invention relates to a compound represented by Formula (I): (wherein Ar 1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar 2 represents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; X 1 represents (1) —C≡C— or (2) a double bond etc. which may be substituted; R 1 and R 2 represent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted) or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents. The object of the present invention is to find a therapeutic or preventive agent for diseases caused by Aβ. According to the present invention, a therapeutic or preventive agents for diseases caused by Aβ can be provided.

  本发明涉及一种由式（I）表示的化合物：（其中Ar1代表可以被1到3个取代基取代的咪唑基团；Ar2代表可以被1到3个取代基取代的吡啶基团、嘧啶基团或苯基；X1代表（1）-C≡C-或（2）可以被取代的双键等；R1和R2代表，例如，可以被取代的C1-6烷基或C3-8环烷基等）或其药理学上可接受的盐，并且用作药物剂。本发明的目的是寻找一种治疗或预防由Aβ引起的疾病的药剂。根据本发明，可以提供治疗或预防由Aβ引起的疾病的药剂。
• Diphenylalkylamine derivatives useful as opioid receptor agonists
  申请人：——

  公开号：US20030176693A1

  公开（公告）日：2003-09-18

  A substance having affinity for an opioid &dgr; receptor, which is represented by the following general formula (I): 1 wherein, X represents a group of the general formula: —CO—N(R 5 )(R 6 ) (II) and the like, n represents 1 to 3, R 1 and R 2 represent a hydrogen atom, a halogen atom, a lower alkyl group and the like, R 3 represents a hydrogen atom, a halogen atom, a lower alkyl group and the like, R 4 represents a saturated or unsaturated monocyclic or bicyclic carbocyclic group and the like, R 5 to R 12 represent a hydrogen atom, a lower alkyl group and the like, and R 3 and R 4 , R 5 and R 6 , R 7 or R 8 and R 9 and R 10 may bind to each other to form a cyclic structure, and a medicament useful for preventive and/or therapeutic treatment of central nervous system diseases and peripheral nervous system diseases comprising the substance as an active ingredient.

  一种具有与阿片受体δ亲和力的物质，其由以下一般公式（I）表示：其中，X代表一般公式的一个基团：—CO—N（R5）（R6）（II）等，n代表1至3，R1和R2代表氢原子、卤素原子、低碳烷基团等，R3代表氢原子、卤素原子、低碳烷基团等，R4代表饱和或不饱和的单环或双环碳环基团等，R5到R12代表氢原子、低碳烷基团等，R3和R4、R5和R6、R7或R8和R9以及R10可能相互结合形成环状结构，并且包括该物质作为活性成分的用于预防和/或治疗中枢神经系统疾病和外周神经系统疾病的药物。
• Phenoxyalkylamine derivatives useful as opioid delta receptor ligands
  申请人：Tsushima Masaki

  公开号：US20050148583A1

  公开（公告）日：2005-07-07

  A medicament useful for preventive and/or therapeutic treatment of nerve system diseases which comprises, as an active ingredient, a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof: wherein, X represents a group represented by the following general formula (II), (III), (IV), (V), or (VI), “A” represents a saturated or unsaturated 3- to 6-membered carbocyclic group and the like, “B” represents CH 2 and the like, “n” represents 0 to 2, R 1 represents a hydrogen atom, a halogen atom and the like, R 2 , R 3 , and R 7 to R 14 represent a hydrogen atom, a lower alkyl group which may be substituted and the like, R 4 represents a hydrogen atom, a lower alkyl group which may be substituted and the like, R 5 represents a hydrogen atom, a halogen atom and the like, R 6 represents a saturated or unsaturated monocyclic or bicyclic carbocyclic group and the like, and R 5 and R 6 , R 7 and R 8 , R 9 and R 10 , or R 11 and R 12 may bind to each other to form a cyclic structure.

  一种用于神经系统疾病的预防和/或治疗的药物，其包括以下通式（I）所表示的化合物或其药学上可接受的盐作为活性成分： 其中，X代表以下通式（II），（III），（IV），（V）或（VI）所表示的基团，“A”代表饱和或不饱和的3-至6-成员的碳环基团等，“B”代表CH2等，“n”代表0至2，“R1”代表氢原子，卤原子等，“R2”，“R3”和“R7”至“R14”代表氢原子，可被取代的较低烷基基团等，“R4”代表氢原子，可被取代的较低烷基基团等，“R5”代表氢原子，卤原子等，“R6”代表饱和或不饱和的单环或双环碳环基团等，“R5”和“R6”，“R7”和“R8”，“R9”和“R10”，或“R11”和“R12”可以结合在一起形成环状结构。
• Sulfonamide compounds, their preparation and use
  申请人：——

  公开号：US20040267010A1

  公开（公告）日：2004-12-30

  Compounds possessing 5HT7 activity of formula (I) or a pharmaceutically acceptable salt thereof are disclosed: 1 in which X is a 5 or 6 membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur; R 2 is halogen, C 1-6 alkyl, haloC 1-6 alkyl, hydroxy, C 1-6 alkoxy or C 1-6 alkylthio; R 3 is hydrogen, C 1-6 alkyl, hydroxy or oxo; m is 0, 1 or 2; p is 0, 1 or 2; n is 1 or 2; R 4 and R 5 are both hydrogen, or R 4 and R 5 combine together to form a further group: —(CH 2 )q- where q is 2 or 3; D is a single bond, C 1-4 alkylene, C═O or oxygen; Z is either a group (a): 2 in which R 1 is halogen, C 1 - 6 alkyl, cyano, haloC 1-6 alkyl, C 3 - 7 cycloalkyl, C 1 - 6 alkoxy, hydroxy, amino, mono- or di-C 1 - 6 alkylamino, acylamino, nitro, carboxy, C 1 - 6 alkoxycarbonyl, C 1 - 6 alkylthio, C 1 - 6 alkylsulfinyl, C 1 - 6 alkylsulfonyl, sulfamoyl, mono- and di-C 1 - 6 alkylsulfamoyl, carbamoyl, mono- or di-C 1 - 6 alkylcarbamoyl, C 1 - 6 alkylsulfonamido, arylsulfonamido, aryl, arylC 1 - 6 alkyl, arylC 1 - 6 alkoxy, aryloxy or arylthio, and y is 0, 1, 2 or 3; or a group (b): 3 in which P is a 5 membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur; R 8 is hydrogen, C 1-6 alkyl, hydroxy or oxo; R 6 and R 7 form the residue of a phenyl ring or a 6 membered heteroaryl ring comprising from one to three heteroatoms selected from nitrogen, oxygen and sulfur and optionally substituted with one or two substitutents which may be the same or different and selected from the group consisting of halogen, C 1 - 6 alkyl, cyano, haloC 1-6 alkyl, C 3 - 7 cycloalkyl, C 1 - 6 alkoxy, hydroxy, amino, mono- or di-C 1 - 6 alkylamino, acylamino, nitro, carboxy, C 1 - 6 alkoxycarbonyl, C 1 - 6 alkylthio, C 1 - 6 alkylsulfinyl, C 1 - 6 alkylsulfonyl, sulfamoyl, mono- and di-C 1 - 6 alkylsulfamoyl, carbamoyl, mono- and di-C 1 - 6 alkylcarbamoyl, C 1 - 6 alkylsulfonamido, arylsulfonamido, aryl, arylC 1 - 6 alkyl, arylC 1 - 6 alkoxy, aryloxy and arylthio. Also disclosed are processes for preparation of the compounds, and uses in the treatment of CNS and other disorders.

  本文披露了具有5HT7活性的化合物的公式（I）或其药学上可接受的盐：其中X是含有1至3个氧、氮和硫杂原子的5或6元杂环环，R2为卤素、C1-6烷基、卤代C1-6烷基、羟基、C1-6烷氧基或C1-6烷基硫醚；R3为氢、C1-6烷基、羟基或氧代；m为0、1或2；p为0、1或2；n为1或2；R4和R5均为氢，或R4和R5结合形成另一基团：-（CH2）q-其中q为2或3；D为单键、C1-4烷基、C═O或氧；Z为以下两种基团之一：（a）其中R1为卤素、C1-6烷基、氰基、卤代C1-6烷基、C3-7环烷基、C1-6烷氧基、羟基、氨基、单-或双C1-6烷基氨基、酰胺基、硝基、羧基、C1-6烷氧羰基、C1-6烷基硫醇基、C1-6烷基亚磺酰基、磺酰胺基、单-和双C1-6烷基磺酰胺基、氨基甲酰基、单-或双C1-6烷基氨基甲酰基、C1-6烷基磺酰胺基、芳基磺酰胺基、芳基、芳基C1-6烷基、芳基C1-6烷氧基、芳氧基或芳硫醚基，y为0、1、2或3；或（b）其中P为含有1至3个氧、氮和硫杂原子的5元杂环环，R8为氢、C1-6烷基、羟基或氧代；R6和R7形成苯环或含有从一个到三个氮、氧和硫杂原子的6元杂环环的残基，且可选择地被一个或两个取代基取代，所述取代基可能相同或不同，并从以下基团中选择：卤素、C1-6烷基、氰基、卤代C1-6烷基、C3-7环烷基、C1-6烷氧基、羟基、氨基、单-或双C1-6烷基氨基、酰胺基、硝基、羧基、C1-6烷氧羰基、C1-6烷基硫醇基、C1-6烷基亚磺酰基、磺酰胺基、单-和双C1-6烷基磺酰胺基、氨基甲酰基、单-或双C1-6烷基氨基甲酰基、C1-6烷基磺酰胺基、芳基磺酰胺基、芳基、芳基C1-6烷基、芳基C1-6烷氧基、芳氧基或芳硫醚基。本文还披露了制备这些化合物的方法以及在治疗中枢神经系统和其他疾病中的用途。